Scientists investigated the inhibitory potential of six pyruvate dehydrogenase kinase-1 inhibitors on cellular proliferation, migration, and invasion of androgen-sensitive LNCaP and androgen-negative PC-3 prostate cancer cells.
[European Journal of Pharmacology]